Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus sulfasalazine in non-resectable pancreatic ductal adenocarcinoma
2006-005104-14Phase 3Active
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of gemcitabine and 5-aminosalicylic acid + sulphasalazine in pancreatic adenocarcinoma (PDAC), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Number of treatment days. Started Jun 2007; status: active.
02
Drugs
gemcitabine5-aminosalicylic acid + sulphasalazine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2006-005104-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005104-14.